Korean Guideline for the Prevention and Treatment of Glucocorticoid-induced Osteoporosis

• Published in: Journal of rheumatic diseases Vol. 25; no. 4; pp. 263 - 295
• Main Authors: Park, So Young, Gong, Hyun Sik, Kim, Kyoung Min, Kim, Dam, Kim, Hayoung, Jeon, Chan Hong, Ju, Ji Hyeon, Lee, Shin-Seok, Park, Dong Ah, Sung, Yoon-Kyoung, Kim, Sang Wan
• Format: Journal Article
• Language: English
• Published: 대한류마티스학회 01.10.2018
• Subjects: 내과학
• ISSN: 2093-940X; 2233-4718
• DOI: 10.4078/jrd.2018.25.4.263

Objective. To develop guidelines and recommendations to prevent and treat glucocorticoid-induced osteoporosis (GIOP) in Korea. Methods. The Korean Society for Bone and Mineral Research and the Korean College of Rheumatology developed this guideline based on Guidance for the Development of Clinical Practice Guidelines version 1.0 established by the National Evidence-Based Healthcare Collaborating Agency. This guideline was developed by adapting previously-published guidelines, and a systematic review and quality assessment were conducted. Results. This guideline applies to adults aged 19 years or older who are using or plan to use glucocorticoids (GCs), but does not include children and adolescents. An initial assessment of fracture risk should be performed within 6 months of initial GC use. Fracture risk should be estimated using FRAX (Fracture Risk Assessment Tool) with adjustments for GC dose, previous osteoporotic fracture history, and bone mineral density (BMD) results. All patients taking more than 2.5 mg/day prednisolone or equivalent for more than 3 months are recommended to take adequate calcium and vitamin D. Patients at moderate to high fracture risk should be treated with additional osteoporosis medication. All patients continuing GC therapy should receive an annual BMD measurement, vertebral X-ray, and fracture risk assessment using FRAX. When a treatment failure is suspected, switching to another drug should be considered. Conclusion. This guideline is intended to provide guidance for clinicians in prevention and treatment of GIOP. KCI Citation Count: 1